Diatide signs license deal with Angstrom

Article

Radiopharmaceutical firm Diatide last month signed a license agreement with Angstrom Pharmaceuticals that will allow Angstrom to develop cancer-fighting pharmaceuticals. Londonderry, NH-based Diatide will have global exclusive rights to imaging and

Radiopharmaceutical firm Diatide last month signed a license agreement with Angstrom Pharmaceuticals that will allow Angstrom to develop cancer-fighting pharmaceuticals. Londonderry, NH-based Diatide will have global exclusive rights to imaging and therapeutic agents produced from Angstrom’s tumor-targeting technology. Diatide will pay San Diego-based Angstrom an initial payment, future research and milestone payments, and royalties on product sales, and will provide research support.

Angstrom has developed and patented small cyclic peptides that bind to a key receptor found on the surface of almost all solid tumors, including breast, prostate, colon, and lung. The two firms believe that targeting these receptors with radiotherapeutic agents could obstruct tumor growth.

Recent Videos
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
Related Content
© 2025 MJH Life Sciences

All rights reserved.